A Phase I/II Study of Cabazitaxel Combined With Abiraterone Acetate and Prednisone in Patients With Metastatic Castrate-Resistant Prostate Cancer (CRPC) Whose Disease Has Progressed After Docetaxel Chemotherapy

Trial Profile

A Phase I/II Study of Cabazitaxel Combined With Abiraterone Acetate and Prednisone in Patients With Metastatic Castrate-Resistant Prostate Cancer (CRPC) Whose Disease Has Progressed After Docetaxel Chemotherapy

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Jan 2017

At a glance

  • Drugs Cabazitaxel (Primary) ; Abiraterone acetate; Prednisone
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 03 Nov 2015 According to the ClinicalTrials.gov record, the treatment table has been amended.
    • 13 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top